Gene drives: an edit that spreads itself
Normally an edited gene obeys the ordinary rules of inheritance: a parent passes it to only about half its offspring. So an introduced change tends to *dilute* across generations unless it gives a strong survival edge. A gene drive breaks that rule on purpose.
The idea: build an edit that also carries CRISPR instructions to copy itself onto the matching chromosome inside the new individual. Now a child who inherits the edit from one parent ends up with it on *both* chromosomes — so it passes to nearly *all* of its offspring, not half. Run that forward and the change can sweep through an entire wild population in a modest number of generations, sharply driving up its allele frequency far faster than natural selection alone would allow.
Body cells vs the germline
The single most important ethical line in human editing is the difference between two kinds of cells. Editing a person's body cells — muscle, blood, liver — changes a somatic target: it affects that patient and stops with them. Editing the germline — eggs, sperm, or an embryo — changes cells that become the next person, so the edit is passed to that person's children and all descendants.
That difference changes everything. Somatic editing, the basis of emerging gene therapy, is broadly accepted in principle: a consenting patient weighs a treatment for their own condition, much like other medicine. Germline editing is a different matter entirely — the people most affected (future children) cannot consent, the change is permanent in the family line, and our ability to predict every consequence is limited. For these reasons, heritable editing of human embryos intended for pregnancy is widely restricted or banned, and the broad scientific consensus is that it is not currently responsible to do.
- Somatic editing: affects one patient's body cells; not inherited; the basis of current gene therapies.
- Germline editing: changes eggs, sperm, or embryos; the change is heritable by all descendants.
- Future children can't consent and effects are permanent — so heritable human editing is widely restricted.
Honest limits, real promise
It helps to be clear-eyed about what today's editing can and cannot do. On the limits side: getting the editor into the right cells of a living body (delivery) is often the hardest step; off-target cuts can occur and must be checked for; many traits and diseases involve many genes plus environment, so they cannot be “fixed” with one tidy edit; and editing a cell is not the same as curing a person.
On the promise side, the progress is genuine. Approved somatic gene therapies now exist for certain inherited blood disorders, where a patient's own cells are edited outside the body and returned. In the lab, CRISPR screens probe what thousands of genes do; in farming, editing tunes crops without foreign genes. The honest summary is neither hype nor fear: a fast-moving, powerful set of tools whose benefits arrive fastest where the science is mature, the delivery is solved, and the ethics — especially that body-cell-versus-germline line — are taken seriously.